170 related articles for article (PubMed ID: 26298289)
1. AuNP flares-capped mesoporous silica nanoplatform for MTH1 detection and inhibition.
Gao W; Cao W; Sun Y; Wei X; Xu K; Zhang H; Tang B
Biomaterials; 2015 Nov; 69():212-21. PubMed ID: 26298289
[TBL] [Abstract][Full Text] [Related]
2. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy.
Huber KV; Salah E; Radic B; Gridling M; Elkins JM; Stukalov A; Jemth AS; Göktürk C; Sanjiv K; Strömberg K; Pham T; Berglund UW; Colinge J; Bennett KL; Loizou JI; Helleday T; Knapp S; Superti-Furga G
Nature; 2014 Apr; 508(7495):222-7. PubMed ID: 24695225
[TBL] [Abstract][Full Text] [Related]
3. (S)-crizotinib induces apoptosis in human non-small cell lung cancer cells by activating ROS independent of MTH1.
Dai X; Guo G; Zou P; Cui R; Chen W; Chen X; Yin C; He W; Vinothkumar R; Yang F; Zhang X; Liang G
J Exp Clin Cancer Res; 2017 Sep; 36(1):120. PubMed ID: 28882182
[TBL] [Abstract][Full Text] [Related]
4. Influence of Chirality of Crizotinib on Its MTH1 Protein Inhibitory Activity: Insight from Molecular Dynamics Simulations and Binding Free Energy Calculations.
Niu Y; Pan D; Shi D; Bai Q; Liu H; Yao X
PLoS One; 2015; 10(12):e0145219. PubMed ID: 26677850
[TBL] [Abstract][Full Text] [Related]
5. Augment of Oxidative Damage with Enhanced Photodynamic Process and MTH1 Inhibition for Tumor Therapy.
Hu JJ; Chen Y; Li ZH; Peng SY; Sun Y; Zhang XZ
Nano Lett; 2019 Aug; 19(8):5568-5576. PubMed ID: 31262183
[TBL] [Abstract][Full Text] [Related]
6. Delivery of MTH1 inhibitor (TH287) and MDR1 siRNA via hyaluronic acid-based mesoporous silica nanoparticles for oral cancers treatment.
Shi XL; Li Y; Zhao LM; Su LW; Ding G
Colloids Surf B Biointerfaces; 2019 Jan; 173():599-606. PubMed ID: 30352381
[TBL] [Abstract][Full Text] [Related]
7. Validation and development of MTH1 inhibitors for treatment of cancer.
Warpman Berglund U; Sanjiv K; Gad H; Kalderén C; Koolmeister T; Pham T; Gokturk C; Jafari R; Maddalo G; Seashore-Ludlow B; Chernobrovkin A; Manoilov A; Pateras IS; Rasti A; Jemth AS; Almlöf I; Loseva O; Visnes T; Einarsdottir BO; Gaugaz FZ; Saleh A; Platzack B; Wallner OA; Vallin KS; Henriksson M; Wakchaure P; Borhade S; Herr P; Kallberg Y; Baranczewski P; Homan EJ; Wiita E; Nagpal V; Meijer T; Schipper N; Rudd SG; Bräutigam L; Lindqvist A; Filppula A; Lee TC; Artursson P; Nilsson JA; Gorgoulis VG; Lehtiö J; Zubarev RA; Scobie M; Helleday T
Ann Oncol; 2016 Dec; 27(12):2275-2283. PubMed ID: 27827301
[TBL] [Abstract][Full Text] [Related]
8. Synergistic therapy of chemotherapeutic drugs and MTH1 inhibitors using a pH-sensitive polymeric delivery system for oral squamous cell carcinoma.
Li X; Li L; Huang Y; Liu B; Chi H; Shi L; Zhang W; Li G; Niu Y; Zhu X
Biomater Sci; 2017 Sep; 5(10):2068-2078. PubMed ID: 28744533
[TBL] [Abstract][Full Text] [Related]
9. Cancer therapy. Targeting the poison within.
Smits VA; Gillespie DA
Cell Cycle; 2014; 13(15):2330-3. PubMed ID: 25483183
[TBL] [Abstract][Full Text] [Related]
10. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool.
Gad H; Koolmeister T; Jemth AS; Eshtad S; Jacques SA; Ström CE; Svensson LM; Schultz N; Lundbäck T; Einarsdottir BO; Saleh A; Göktürk C; Baranczewski P; Svensson R; Berntsson RP; Gustafsson R; Strömberg K; Sanjiv K; Jacques-Cordonnier MC; Desroses M; Gustavsson AL; Olofsson R; Johansson F; Homan EJ; Loseva O; Bräutigam L; Johansson L; Höglund A; Hagenkort A; Pham T; Altun M; Gaugaz FZ; Vikingsson S; Evers B; Henriksson M; Vallin KS; Wallner OA; Hammarström LG; Wiita E; Almlöf I; Kalderén C; Axelsson H; Djureinovic T; Puigvert JC; Häggblad M; Jeppsson F; Martens U; Lundin C; Lundgren B; Granelli I; Jensen AJ; Artursson P; Nilsson JA; Stenmark P; Scobie M; Berglund UW; Helleday T
Nature; 2014 Apr; 508(7495):215-21. PubMed ID: 24695224
[TBL] [Abstract][Full Text] [Related]
11. Human MutT homologue 1 mRNA overexpression correlates to poor response of multiple myeloma.
Zhou H; Jian Y; Leng Y; Liu N; Tian Y; Wang G; Gao W; Yang G; Chen W
Int J Hematol; 2017 Mar; 105(3):318-325. PubMed ID: 27848179
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a new class of MTH1 inhibitor by X-ray crystallographic screening.
Yokoyama T; Kitakami R; Mizuguchi M
Eur J Med Chem; 2019 Apr; 167():153-160. PubMed ID: 30771603
[TBL] [Abstract][Full Text] [Related]
13. Identification of potent and selective MTH1 inhibitors.
Petrocchi A; Leo E; Reyna NJ; Hamilton MM; Shi X; Parker CA; Mseeh F; Bardenhagen JP; Leonard P; Cross JB; Huang S; Jiang Y; Cardozo M; Draetta G; Marszalek JR; Toniatti C; Jones P; Lewis RT
Bioorg Med Chem Lett; 2016 Mar; 26(6):1503-1507. PubMed ID: 26898335
[TBL] [Abstract][Full Text] [Related]
14. Potent and specific MTH1 inhibitors targeting gastric cancer.
Zhou W; Ma L; Yang J; Qiao H; Li L; Guo Q; Ma J; Zhao L; Wang J; Jiang G; Wan X; Adam Goscinski M; Ding L; Zheng Y; Li W; Liu H; Suo Z; Zhao W
Cell Death Dis; 2019 Jun; 10(6):434. PubMed ID: 31164636
[TBL] [Abstract][Full Text] [Related]
15. Proteomic profiling of small-molecule inhibitors reveals dispensability of MTH1 for cancer cell survival.
Kawamura T; Kawatani M; Muroi M; Kondoh Y; Futamura Y; Aono H; Tanaka M; Honda K; Osada H
Sci Rep; 2016 May; 6():26521. PubMed ID: 27210421
[TBL] [Abstract][Full Text] [Related]
16. Identification and structure-activity relationship of purine derivatives as novel MTH1 inhibitors.
Kumar A; Kawamura T; Kawatani M; Osada H; Zhang KYJ
Chem Biol Drug Des; 2017 Jun; 89(6):862-869. PubMed ID: 27863017
[TBL] [Abstract][Full Text] [Related]
17. Inhibitor development of MTH1 via high-throughput screening with fragment based library and MTH1 substrate binding cavity.
Peng C; Li YH; Yu CW; Cheng ZH; Liu JR; Hsu JL; Hsin LW; Huang CT; Juan HF; Chern JW; Cheng YS
Bioorg Chem; 2021 May; 110():104813. PubMed ID: 33774493
[TBL] [Abstract][Full Text] [Related]
18. Photoinduced intracellular controlled release drug delivery in human cells by gold-capped mesoporous silica nanosphere.
Vivero-Escoto JL; Slowing II; Wu CW; Lin VS
J Am Chem Soc; 2009 Mar; 131(10):3462-3. PubMed ID: 19275256
[TBL] [Abstract][Full Text] [Related]
19. Novel Class of Potent and Cellularly Active Inhibitors Devalidates MTH1 as Broad-Spectrum Cancer Target.
Ellermann M; Eheim A; Rahm F; Viklund J; Guenther J; Andersson M; Ericsson U; Forsblom R; Ginman T; Lindström J; Silvander C; Trésaugues L; Giese A; Bunse S; Neuhaus R; Weiske J; Quanz M; Glasauer A; Nowak-Reppel K; Bader B; Irlbacher H; Meyer H; Queisser N; Bauser M; Haegebarth A; Gorjánácz M
ACS Chem Biol; 2017 Aug; 12(8):1986-1992. PubMed ID: 28679043
[TBL] [Abstract][Full Text] [Related]
20. Radiolabeled 6-(2, 3-Dichlorophenyl)-N4-methylpyrimidine-2, 4-diamine (TH287): A Potential Radiotracer for Measuring and Imaging MTH1.
Chen H; Afrin S; Guo Y; Chu W; Benzinger TLS; Rogers BE; Garbow JR; Perlmutter JS; Zhou D; Xu J
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33238630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
